- Home
- FSCO vs CDTX Comparison
FSCO vs CDTX Comparison
Compare FSCO & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSCO
- CDTX
- Stock Information
- Founded
- FSCO 2013
- CDTX 2012
- Country
- FSCO United States
- CDTX United States
- Employees
- FSCO N/A
- CDTX N/A
- Industry
- FSCO Trusts Except Educational Religious and Charitable
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSCO Finance
- CDTX Health Care
- Exchange
- FSCO Nasdaq
- CDTX Nasdaq
- Market Cap
- FSCO 1.4B
- CDTX 1.6B
- IPO Year
- FSCO N/A
- CDTX 2015
- Fundamental
- Price
- FSCO $7.43
- CDTX $64.71
- Analyst Decision
- FSCO
- CDTX Strong Buy
- Analyst Count
- FSCO 0
- CDTX 11
- Target Price
- FSCO N/A
- CDTX $57.00
- AVG Volume (30 Days)
- FSCO 709.7K
- CDTX 495.2K
- Earning Date
- FSCO 01-01-0001
- CDTX 11-06-2025
- Dividend Yield
- FSCO 11.44%
- CDTX N/A
- EPS Growth
- FSCO N/A
- CDTX N/A
- EPS
- FSCO N/A
- CDTX N/A
- Revenue
- FSCO N/A
- CDTX N/A
- Revenue This Year
- FSCO N/A
- CDTX N/A
- Revenue Next Year
- FSCO N/A
- CDTX N/A
- P/E Ratio
- FSCO N/A
- CDTX N/A
- Revenue Growth
- FSCO N/A
- CDTX N/A
- 52 Week Low
- FSCO $4.08
- CDTX $10.14
- 52 Week High
- FSCO $6.00
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- FSCO 52.40
- CDTX 52.23
- Support Level
- FSCO $7.40
- CDTX N/A
- Resistance Level
- FSCO $7.49
- CDTX $65.85
- Average True Range (ATR)
- FSCO 0.06
- CDTX 2.92
- MACD
- FSCO -0.00
- CDTX -2.69
- Stochastic Oscillator
- FSCO 55.94
- CDTX 93.50
About FSCO FS Credit Opportunities Corp.
FS Credit Opportunities Corp is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. It predominantly invests in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments. The credit instruments in which it invests typically are rated below investment grade by rating agencies or would be rated below investment grade if rated. To achieve its investment objectives, the fund focuses on strategies such as Opportunistic Credit, Special Situations, and Capital Structure Solutions.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.